Sector News

What's holding up the Shire-Baxalta deal? One word: Taxes

January 8, 2016
Life sciences

Shire and Baxalta both reportedly want to make a tie-up happen. So what’s taking so long?

According to the Financial Times, the potential deal now hinges on Shire’s ability to put cash in the mix without triggering a hefty tax bill. And the Dublin drugmaker won’t be proceeding until it’s “highly confident” in the advice it receives, the newspaper’s sources say.

Shire initially approached its target with an all-stock bid–one that would have avoided violating U.S. rules that forbid spinoffs–such as Baxalta, which separated from parent Baxter this summer–from funneling tax-free cash to shareholders. But Baxalta wasn’t interested in an all-stock deal, and now, Shire is working with advisers to make sure adding cash to its offer won’t create a liability.

If it does, Shire could always argue against it in court, where it would have to prove Baxter wasn’t planning to use the spinoff for tax avoidance all along, Bernstein analyst Ronny Gal pointed out in a note to shareholders. On that front, Shire has a couple points going for it. “Baxter didn’t know that Shire was interested, and from its incorporation documents it is clear that Baxalta does not want to be bought,” he wrote.

Before it takes that risk, though, Shire likely needs some clarity on a couple items, Gal figures. For one, it needs to make sure there’s no “aberrant email somewhere suggesting that internally Baxter thought the Baxalta spin-out may lead to its profitable acquisition.” And it also probably wants to know “the exact magnitude of its tax exposure,” as well as whose rights and responsibilities are whose if the IRS comes calling.

If Shire can get that all figured out, CEO Flemming Ornskov may wind up sealing the deal he’s been chasing for months. As Bloomberg recently reported, Shire is offering to fork over between $46.50 and $48 per share for the Illinois pharma–a price that values the company at around $32 billion.

Not everyone is as gung-ho about the potential acquisition as Ornskov, though. Gal, for one, has pointed out that several companies have new-age hemophilia treatments coming up the pipeline that’ll threaten Baxalta’s top dogs. “Success of alternative approaches could devastate” Baxalta’s business, he wrote last month, predicting that 40% or so could take a direct hit.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach